Cirino Botta
Cirino Botta
Assistant Professor, University of Palermo
Email verificata su
Citata da
Citata da
miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease
M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ...
Journal of cellular physiology 228 (7), 1506-1515, 2013
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials
D Ciliberto, C Botta, P Correale, M Rossi, M Caraglia, P Tassone, ...
European Journal of Cancer, 2012
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies
N Amodio, M Rossi, L Raimondi, MR Pitari, C Botta, P Tagliaferri, ...
Oncotarget 6 (15), 12837, 2015
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
E Morelli, E Leone, ME Cantafio, MT Di Martino, N Amodio, L Biamonte, ...
Leukemia 29 (11), 2173-2183, 2015
A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells
A Gulla, MT Di Martino, ME Gallo Cantafio, E Morelli, N Amodio, C Botta, ...
Clinical cancer research 22 (5), 1222-1233, 2016
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
MR Pitari, M Rossi, N Amodio, C Botta, E Morelli, C Federico, A GullÓ, ...
Oncotarget 6 (29), 27343, 2015
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients
C Botta, V Barbieri, D Ciliberto, A Rossi, D Rocco, R Addeo, N Staropoli, ...
Cancer biology & therapy 14 (6), 469-475, 2013
A p53‐dependent tumor suppressor network is induced by selective miR‐125a‐5p inhibition in multiple myeloma cells
M Leotta, L Biamonte, L Raimondi, D Ronchetti, MT Di Martino, C Botta, ...
Journal of cellular physiology 229 (12), 2106-2116, 2014
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
C Perez, C Botta, A Zabaleta, N Puig, MT Cedena, I Goicoechea, ...
Blood, The Journal of the American Society of Hematology 136 (2), 199-209, 2020
Cetuximab▒chemotherapy enhances dendritic cell‐mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen‐specific cytotoxic T‐cellá…
P Correale, C Botta, MG Cusi, MT Del Vecchio, MM De Santi, ...
International journal of cancer 130 (7), 1577-1589, 2012
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma
P Correale, MS Rotundo, C Botta, MT Del Vecchio, C Ginanneschi, ...
Clinical cancer research 18 (3), 850-857, 2012
Bortezomib induces anti–multiple myeloma immune response mediated by cGAS/STING pathway activation
A Gulla, E Morelli, MK Samur, C Botta, T Hideshima, G Bianchi, M Fulciniti, ...
Blood cancer discovery 2 (5), 468-483, 2021
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities
C Botta, A GullÓ, P Correale, P Tagliaferri, P Tassone
Frontiers in oncology 4, 348, 2014
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse
V Nardone, C Botta, M Caraglia, EC Martino, MR Ambrosio, T Carfagno, ...
Cancer biology & therapy 17 (11), 1213-1220, 2016
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
EC Martino, G Misso, P Pastina, S Costantini, F Vanni, C Gandolfo, ...
Cell death discovery 2 (1), 1-8, 2016
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis
M Arbitrio, MT Di Martino, V Barbieri, G Agapito, PH Guzzi, C Botta, ...
Cancer chemotherapy and pharmacology 77, 205-209, 2016
Iron metabolism in the tumor microenvironment—Implications for anti-cancer immune response
A Sacco, AM Battaglia, C Botta, I Aversa, S Mancuso, F Costanzo, ...
Cells 10 (2), 303, 2021
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients
C Botta, D Ciliberto, M Rossi, N Staropoli, M Cuce, T Galeano, ...
Blood advances 1 (7), 455-466, 2017
Radiomics predicts survival of patients with advanced non‑small cell lung cancer undergoing PD‑1 blockade using Nivolumab
V Nardone, P Tini, P Pastina, C Botta, A Reginelli, SF Carbone, ...
Oncology Letters 19 (2), 1559-1566, 2020
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells
C Botta, M Cuce, MR Pitari, D Caracciolo, A Gulla, E Morelli, C Riillo, ...
Leukemia 32 (4), 1003-1015, 2018
Il sistema al momento non pu˛ eseguire l'operazione. Riprova pi¨ tardi.
Articoli 1–20